Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lintuzumab Bi-213

Drug Profile

Lintuzumab Bi-213

Alternative Names: Anti-CD33 monoclonal antibody M195 Bi-213; Bi213 MOAB M195; Bi213 monoclonal antibody M195; Bismab-A; Bismuth-213 HuM195; Bismuth-213 lintuzumab; Bismuth-213-labelled HuM195; HuM195-Bi-213; Lintuzumab bismuth-213; Monoclonal antibody M195 Bi-213 conjugate; Monoclonal antibody M195 bismuth-213; SMART M195 bismuth-213

Latest Information Update: 17 Jun 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Developer Actinium Pharmaceuticals
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD33 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 17 Jun 2013 Discontinued - Phase-I/II for Acute myeloid leukaemia in USA (IV)
  • 13 Jun 2012 Clinical development is ongoing in USA
  • 09 Dec 2008 Adverse events and efficacy data from a phase I/II trial in Acute myeloid leukaemia presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top